SK285210B6 - Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva - Google Patents

Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva Download PDF

Info

Publication number
SK285210B6
SK285210B6 SK448-99A SK44899A SK285210B6 SK 285210 B6 SK285210 B6 SK 285210B6 SK 44899 A SK44899 A SK 44899A SK 285210 B6 SK285210 B6 SK 285210B6
Authority
SK
Slovakia
Prior art keywords
epa
combination
acid
treatment
schizophrenia
Prior art date
Application number
SK448-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK44899A3 (en
Inventor
David Frederick Horrobin
Original Assignee
Scarista Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621294.9A external-priority patent/GB9621294D0/en
Application filed by Scarista Limited filed Critical Scarista Limited
Publication of SK44899A3 publication Critical patent/SK44899A3/sk
Publication of SK285210B6 publication Critical patent/SK285210B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK448-99A 1996-10-11 1997-10-07 Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva SK285210B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621294.9A GB9621294D0 (en) 1996-10-11 1996-10-11 Fatty acid treatment
GBGB9626062.5A GB9626062D0 (en) 1996-10-11 1996-12-16 Fatty acid treatment
PCT/GB1997/002738 WO1998016216A1 (en) 1996-10-11 1997-10-07 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Publications (2)

Publication Number Publication Date
SK44899A3 SK44899A3 (en) 2000-08-14
SK285210B6 true SK285210B6 (sk) 2006-09-07

Family

ID=26310221

Family Applications (1)

Application Number Title Priority Date Filing Date
SK448-99A SK285210B6 (sk) 1996-10-11 1997-10-07 Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva

Country Status (25)

Country Link
US (5) US6331568B1 (de)
EP (1) EP0956013B1 (de)
JP (1) JP4151853B2 (de)
KR (2) KR20060061409A (de)
CN (1) CN1109543C (de)
AT (1) ATE236627T1 (de)
AU (1) AU731692C (de)
BR (1) BR9713479A (de)
CA (1) CA2268257C (de)
CZ (1) CZ293704B6 (de)
DE (1) DE69720787T2 (de)
DK (1) DK0956013T3 (de)
ES (1) ES2195175T3 (de)
HK (1) HK1020316A1 (de)
ID (1) ID21473A (de)
IL (1) IL129367A0 (de)
IS (1) IS2180B (de)
NO (1) NO326926B1 (de)
NZ (1) NZ334852A (de)
PL (1) PL190181B1 (de)
PT (1) PT956013E (de)
SK (1) SK285210B6 (de)
TR (1) TR199900786T2 (de)
TW (1) TW429145B (de)
WO (1) WO1998016216A1 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236627T1 (de) * 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
ES2257824T3 (es) * 1998-01-28 2006-08-01 Warner-Lambert Company Llc Metodo para tratar la enfermedad de alzheimer.
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
FR2788437B1 (fr) * 1999-01-14 2006-08-11 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9904895D0 (en) * 1999-03-03 1999-04-28 Scarista Limited Regulators of coenzyme-A-independent transacylase as psychotropic drugs
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
WO2002092779A2 (en) * 2001-05-17 2002-11-21 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
JP2005507754A (ja) 2001-11-08 2005-03-24 アトリウム メディカル コーポレイション 治療薬を含有するコーティングを有する管腔内装置
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
WO2004032824A2 (en) 2002-10-10 2004-04-22 Yeda Research And Development Co. Ltd. Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
EP1660071A1 (de) * 2003-08-18 2006-05-31 Btg International Limited Behandlung von neurodegenerativen erkrankungen
AU2004317087A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
US20090215896A1 (en) * 2004-01-19 2009-08-27 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
EP1765075A4 (de) * 2004-06-10 2010-11-10 Mclean Hospital Corp Pyrimidine, wie z.b. uridin; bei der behandlung von patienten mit manisch-depressiver psychose
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
US7947661B2 (en) * 2004-08-11 2011-05-24 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
WO2006036984A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Stand-alone film and methods for making the same
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US7588931B2 (en) * 2004-11-04 2009-09-15 E. I. Du Pont De Nemours And Company High arachidonic acid producing strains of Yarrowia lipolytica
CA2588166A1 (en) * 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
EP1904049B1 (de) * 2005-07-08 2016-12-07 DSM IP Assets B.V. Mehrfach ungesättigte fettsäuren zur behandlung von demenz und prä-demenz-erkrankungen
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
EP1933991A4 (de) 2005-10-15 2012-05-02 Atrium Medical Corp Hydrophobe vernetzte gele für bioabsorbierbare arzneimittelträgerüberzüge
EP2364701A1 (de) * 2005-12-20 2011-09-14 Cenestra, Llc Zubereitung enthaltend Omega 3 Fettsäuren
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20100130611A1 (en) * 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
US20110190389A1 (en) * 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2008106091A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Use of long-chain alcohol derivatives for the treatment of alopecia areata
US7964751B2 (en) * 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
WO2009046231A1 (en) 2007-10-03 2009-04-09 E. I. Du Pont De Nemours And Company Optimized strains of yarrowia lipolytica for high eicosapentaenoic acid production
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
WO2009086281A1 (en) * 2007-12-21 2009-07-09 Martek Biosciences Corporation Method for preparation of oxylipins
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
US20110166229A1 (en) 2008-09-09 2011-07-07 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
SI2596786T1 (sl) 2009-02-10 2020-03-31 Amarin Pharmaceuticals Ireland Limited, Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
GB0904300D0 (en) 2009-03-12 2009-04-22 Amarin Neuroscience Ltd Essential fatty acid compounds
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK3278665T3 (da) 2009-04-29 2020-11-30 Amarin Pharmaceuticals Ie Ltd Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
US8372465B2 (en) * 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
CA3043081C (en) * 2010-03-04 2020-02-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
EP2593141B1 (de) 2010-07-16 2018-07-04 Atrium Medical Corporation Zusammensetzung und verfahren zur veränderung der geschwindigkeit einer hydrolyse ausgehärteter materialien auf ölbasis
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
EP2540292A1 (de) * 2011-06-28 2013-01-02 Nestec S.A. DHA und EPA zur Reduktion oxidativer Belastung
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (de) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP2017506233A (ja) * 2014-02-07 2017-03-02 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
JP6723509B2 (ja) * 2014-10-24 2020-07-15 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
ES2607715B1 (es) * 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3750536A1 (de) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Verfahren zur verringerung des risikos von kardiovaskulären ereignissen in einem subjekt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8906369D0 (en) 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
CH678181A5 (de) * 1989-05-22 1991-08-15 Nestle Sa
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
EP0457950B1 (de) * 1990-05-23 1993-10-20 Societe Des Produits Nestle S.A. Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
ATE236627T1 (de) * 1996-10-11 2003-04-15 Scarista Ltd Pharmazeutische zubereitung enhaltend eicosapentaensäure und/oder stearidonsäure
US6597649B2 (en) * 1999-05-21 2003-07-22 Matsushita Electric Industrial Co., Ltd. Recordable optical disk

Also Published As

Publication number Publication date
IS2180B (is) 2006-12-15
IS5017A (is) 1999-03-30
CN1233955A (zh) 1999-11-03
AU731692B2 (en) 2001-04-05
DE69720787T2 (de) 2004-03-18
CA2268257C (en) 2008-05-20
CN1109543C (zh) 2003-05-28
US6331568B1 (en) 2001-12-18
NO991635D0 (no) 1999-04-06
NZ334852A (en) 2001-05-25
ATE236627T1 (de) 2003-04-15
US20040048927A1 (en) 2004-03-11
JP2001503743A (ja) 2001-03-21
JP4151853B2 (ja) 2008-09-17
US20030045578A1 (en) 2003-03-06
EP0956013A1 (de) 1999-11-17
NO991635L (no) 1999-06-07
BR9713479A (pt) 2000-04-11
SK44899A3 (en) 2000-08-14
PT956013E (pt) 2003-08-29
HK1020316A1 (en) 2000-04-14
US6624195B2 (en) 2003-09-23
TR199900786T2 (xx) 1999-07-21
PL333423A1 (en) 1999-12-06
NO326926B1 (no) 2009-03-16
EP0956013B1 (de) 2003-04-09
PL190181B1 (pl) 2005-11-30
KR20060061409A (ko) 2006-06-07
ID21473A (id) 1999-06-17
CZ293704B6 (cs) 2004-07-14
CA2268257A1 (en) 1998-04-23
DK0956013T3 (da) 2003-08-04
US20040014810A1 (en) 2004-01-22
KR100657642B1 (ko) 2006-12-19
TW429145B (en) 2001-04-11
AU4566797A (en) 1998-05-11
WO1998016216A1 (en) 1998-04-23
ES2195175T3 (es) 2003-12-01
KR20000049016A (ko) 2000-07-25
IL129367A0 (en) 2000-02-17
CZ115499A3 (cs) 1999-08-11
US20020065319A1 (en) 2002-05-30
AU731692C (en) 2001-10-11
DE69720787D1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
SK285210B6 (sk) Farmaceutický prípravok na liečenie schizofrénie a použitie oleja obsahujúceho kyselinu eikozapentaenovú alebo stearidonovú, alebo ich kombináciu na prípravu tohto liečiva
US5116624A (en) Efa compositions and therapy
AU618814B2 (en) Essential fatty acid compositions
US5116871A (en) Fatty acid therapy and compositions for the treatment of myalgic encephalomyelitis
US6479544B1 (en) Therapeutic combinations of fatty acids
IE59445B1 (en) Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus
NZ227241A (en) Pharmaceutical compositions comprising a cyclosporin and either dihomo-gamma or gamma-linolenic acid and use in combatting the effects of cyclosporin administration
JPH05194244A (ja) 必須脂肪酸を含有する薬剤
EP0246734B1 (de) Eisen enthaltende Zusammensetzung und Verfahren zur Behandlung von Krebs
NZ234528A (en) Use of gla or dgla for preparing a medicament to reduce production of undesirable metabolites from arachidonic acid
JPS6216415A (ja) 月経前症候群治療用医薬組成物およびその治療方法
MXPA99003365A (es) Preparacion farmaceutica que comprende acido eicosapentaenoico y/o acido estearidonico
JPH01156922A (ja) 悩疾患治療用薬剤の製造方法と治療用化合物
IL129367A (en) Pharmaceutical preparations comprising an oil containing eicosapentaenoic acid and/or stearidonic acid for the treatment of psychiatric disorders and a novel stearidonic acid-containing oil therefor
NZ239126A (en) The use of essential fatty acids to treat schizophrenia and associated tardive dyskinesia

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20121007